tracking the news, one byte at a time
Freak Pulse

Alzheimer’s Disease and Frontal Temporal Dementia this week: ImmunoBrain’s IBC-Ab002, a humanized anti-PD-L1 antibody designed to rejuvenate peripheral immune function rather; and A 26-year ARIC cohort analysis of 12,409 Americans found…

Neurodiversity, ADHD, Autism, and AuDHD this week: ASAN is mobilizing public comments against the IACC’s 2026 Strategic Plan, which it says promotes; and A woman diagnosed with autism at 49 recounts her lifelong struggle with masking…

Alzheimer’s Disease and Frontal Temporal Dementia this week: Bristol Myers Squibb has pushed topline readouts for its three ADEPT trials of Cobenfy in Alzheimer’s disease; and At the Alzheimer’s Association International Conference in…

Neurodiversity, ADHD, Autism, and AuDHD this week: Two prominent ADHD researchers argue that the decades-long stimulant-first prescribing paradigm may not serve all; and The neurodiversity movement has reshaped autism from a medical…

Autism Awareness and Community Support this week: The Tallahassee Police Department launched the Care Autism Awareness Initiative with several partner organizations; and The CDC has revised its long-standing statement that vaccines do not…

Research presented in a July 2026 ADDitude webinar shows that stimulant medication does not increase risk for substance use disorder in people with ADHD, and may reduce risk for severe outcomes.

Alzheimer’s Disease and Frontal Temporal Dementia this week: A real-world study presented at AAIC 2026 in London found that the PrecivityAD2 blood test, measuring p-tau217 and; and Johns Hopkins researchers grew hindbrain organoids from…

Alzheimer’s Disease and Frontal Temporal Dementia this week: Biogen’s Phase 2 trial of an anti-tau therapy, BIIB080, showed a 26% reduction in cognitive decline at the lowest; and At AAIC 2026 in London, researchers presented advances in…

Alzheimer’s Disease and Frontal Temporal Dementia this week: A study published in *Neurology* tracked 793 early-onset dementia patients against matched controls using Finnish; and This matters for Alzheimer’s Disease and Frontal Temporal…